Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2185-2190

  Gómez García, Encarna B ^a   Ambergen, Ton ^a   Blok, Marinus J ^a   van den Wijngaard, Arthur ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CLINICAL FEATURE; CONTROLLED STUDY; DNA DETERMINATION; FAMILY HISTORY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVARY CANCER; PATHOGENICITY; PRIORITY JOURNAL; PROBABILITY; ADULT; ANAMNESIS; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PEDIGREE; PROGNOSIS; RETROSPECTIVE STUDY; THEORETICAL MODEL; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL HISTORY TAKING; MIDDLE AGED; MODELS, THEORETICAL; PEDIGREE; PROGNOSIS; RETROSPECTIVE STUDIES; VARIATION (GENETICS);

EID: 17144387531     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.013     Document Type: Article

References (21)

1. National Human Genome Research Institute: Breast Cancer Information Core (BIC) database: An open access on-line breast cancer mutation data base. http://research.nhgri.nih .gov/bic/
2. Arnold N, Peper H, Bandick K, et al: Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. J Chromatogr B 782:99-104, 2002
3. Deffenbaugh AM, Frank TS, Hoffman M, et al: Characterization of common BRCA1 and BRCA2 variants. Genet Test 6:119-121, 2002
4. Fleming MA, Potter JD, Ramirez CJ, et al: Understanding missense mutations in the BRCA1 gene: An evolutionary approach. Proc Natl Acad Sci U S A 100:1151-1156, 2003
5. Petersen GM, Parmigiani G, Thomas D: Missense mutations in disease genes: A Bayesian approach to evaluate causality. Am J Hum Genet 62:1516-1524, 1998
6. Petrucelli N, Lazebnik N, Huelsman KM, et al: Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: A survey of genetic counseling practice. Genet Test 6:107-113, 2002
7. Abkevich V, Zharkikh A, Deffenbaugh AM, et al: Analysis of missense variation in human BRCAI in the context of interspecific sequence variation. J Med Genet 41:492-507, 2004
8. Goldgar DE, Easton DF, Deffenbaugh AM, et al: Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2. Am J Hum Genet 75:535-544, 2004
9. Osorio A, de la Hoya M, Rodríguez-López R, et al: Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 99:305-309, 2002
10. Human Genome Variation Society: Nomenclature for the description of sequence variations. http://www.genomic.unimelb.edu.au/mdi/ mutnomen/recs.html
11. Parmigiani G, Berry DA, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998
12. Frank TS, Manley SA, Olopade OI, et al: Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425, 1998
13. Wagner T, Stoppa-Lyonnet D, Fleischmann E, et al: Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62:369-376, 1999
14. Hogervorst FB, Nederlof PM, Gille JJ, et al: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63:1449-1453, 2003
15. Mazoyer S, Dunning AM, Serova O, et al: A polymorphic stop codon in BRCA2. Nat Genet 14:253-254, 1996
16. Altman DG: Practical Statistics for Medical Research. London, UK, Chapman & Hall, 1991
17. Verhoog LC, Berns EMJJ, Brekelmans CTM, et al: Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18:119S-124S, 2000 (suppl)
18. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002
19. Euhus DM, Smith KC, Robinson L, et al: Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94:844-851, 2002
20. Shannon KM, Lubratovich ML, Finkelstein DM, et al: Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer 94:305-313, 2002
21. De la Hoya M, Diez O, Pérez-Segura P, et al: Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 40:503-610, 2003